MediWound Posts Early Data From Non-Melanoma Skin Cancer Trial
MediWound Ltd (NASDAQ:MDWD) announced initial data from eleven patients in its ongoing open-label Phase 1/2 study of MW005 for low-risk Basal…
ViaCyte Acquisition Can Accelerate Vertex’s Ongoing Type 1 Diabetes Programs
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has agreed to acquire ViaCyte, a privately held biotechnology, for $320 million in cash. ViaCyte is focused…
Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase…
Why Are Pliant Therapeutics Shares Rallying Today?
Pliant Therapeutics Inc’s (NASDAQ:PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and…
Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal
Innoviva Inc (NASDAQ:INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $5.95 per share, representing a premium of approximately 70%…
Arcutis Biotherapeutics Announces Health Canada Accepts For Review New Drug Submission For Roflumilast Cream For Adults And Adolescents With Plaque Psoriasis
Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studies
If approved, roflumilast cream would be the first and
FDA Clears LPCN 2101 IND For Adult Epilepsy Treatment
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system ("CNS") disorders with high unmet medical needs, announced
Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In The Oral Treatment Of Moderate To Severe Psoriasis
Further analysis of Phase III COMFORT™ data show Piclidenoson's superior safety profile and higher patient compliance compared to Otezla®
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a
Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study
MacroGenics Inc (NASDAQ:MGNX) closed the Phase 2 study (CP-MGA271-06) of enoblituzumab in the first-line treatment of patients with recurrent or metastatic…
Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies
Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs and LAD-I.